TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

NCT00415909 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Imatinib Mesylate (IM)
DRUG: TALL-104 cells

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]